Navigation
The antidepressant effects of GLP-1 receptor agonists: a systematic review and meta-analysis
The possible benefits of glucagon-like peptide-1 receptor agonists (GLP-1RAs) for individuals experiencing depression have garnered attention in recent research. This systematic review and meta-analysis aimed to explore the antidepressant potential of these medications.
This investigation included a comprehensive search for randomized controlled trials and prospective cohort studies that contrasted the effects of GLP-1RAs with either placebo or alternative antidiabetic treatments. We utilized several electronic databases, including CENTRAL, PubMed, EMBASE, and others, up until February 16, 2023. A random effects model was employed to assess standardized mean differences in depression ratings between GLP-1RA groups and control groups.
The final analysis encompassed data from 2,071 participants, integrating findings from five randomized controlled trials alongside one prospective cohort study. Results indicated a significant reduction in depression rating scale scores for patients administered GLP-1RAs compared to those receiving control treatments, with a standardized mean difference (SMD) of -0.12 (95% CI [-0.21, -0.03], pSMD <0.01, I2 = 0%, pQ = 0.52). Notably, the subgroup analysis revealed consistent effects of GLP-1RAs on depressive symptoms among individuals with Type 2 diabetes mellitus.
These findings suggest that GLP-1RAs may represent a promising option for the reduction of depressive symptoms in affected adults, warranting further exploration into their application in mental health. [NPID: GLP-1; Systematic review; depression; meta-analysis]
Year: 2026
